Patents by Inventor Aran Frank Labrijn

Aran Frank Labrijn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10465006
    Abstract: The present invention relates to humanized or chimeric antibodies binding CD3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment.
    Type: Grant
    Filed: July 4, 2014
    Date of Patent: November 5, 2019
    Assignee: GENMAB A/S
    Inventors: Edward Van Den Brink, Joost J. Neijssen, Aran Frank Labrijn, Joyce Meesters, Janine Schuurman, Paul Parren
  • Patent number: 10407501
    Abstract: The present invention relates to humanized or chimeric antibodies binding CD3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment.
    Type: Grant
    Filed: January 8, 2015
    Date of Patent: September 10, 2019
    Assignee: GENMAB A/S
    Inventors: Edward Norbert Van Den Brink, Joost J. Neijssen, Aran Frank Labrijn, Joyce Meesters, Janine Schuurman, Isil Altintas, Paul Parren, Rik Rademaker
  • Patent number: 10351629
    Abstract: The invention relates to novel non-human transgenic animals, which upon antigenic stimulation are capable of producing monovalent antibodies binding to a selected antigen, modified heavy chain transgenes, methods for producing the non-human transgenic animals, methods for immunizing the non-human transgenic animals for as well as monovalent antibodies obtainable by such immunization methods.
    Type: Grant
    Filed: March 17, 2016
    Date of Patent: July 16, 2019
    Assignee: GENMAB A/S
    Inventors: Janine Schuurman, Tom Vink, Jan Van De Winkel, Aran Frank Labrijn, Paul Parren, Willem Karel Bleeker, Frank Beurskens, Patrick Van Berkel
  • Patent number: 10344050
    Abstract: The present invention relates to an in vitro method for production of heterodimeric proteins.
    Type: Grant
    Filed: October 26, 2012
    Date of Patent: July 9, 2019
    Assignee: GENMAB A/S
    Inventors: Michael Gramer, Amitava Kundu, Ewald T. J. Van Den Bremer, Muriel Van Kampen, Patrick Priem, Aran Frank Labrijn, Joyce I. Meesters, Joost J. Neijssen, Janine Schuurman, Paul Parren, Patrick Van Berkel, Werner L. Vos, Arnout Gerritsen
  • Publication number: 20180319888
    Abstract: The present invention relates to positions in the constant region of antibodies, in particular the CH3 region of IgG4, which affect the strength of CH3-CH3 interactions. Mutations that either stabilize or destabilize this interaction are disclosed.
    Type: Application
    Filed: May 11, 2018
    Publication date: November 8, 2018
    Inventors: Aran Frank Labrijn, Stefan Loverix, Paul Parren, Jan Van De Winkel, Janine Schuurman, Ignace Lasters
  • Publication number: 20180215827
    Abstract: Isolated monoclonal antibodies which bind to human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.
    Type: Application
    Filed: December 5, 2017
    Publication date: August 2, 2018
    Inventors: Bart DE GOEIJ, Simone DE HAIJ, Thilo RIEDL, Rene HOET, Ole BAADSGAARD, Jan VAN DE WINKEL, David SATIJN, Paul PARREN, Aran Frank LABRIJN, Joyce MEESTERS, Janine SCHUURMAN, Edward N. VAN DEN BRINK
  • Publication number: 20180194845
    Abstract: Isolated monoclonal antibodies which bind to human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.
    Type: Application
    Filed: December 5, 2017
    Publication date: July 12, 2018
    Inventors: Bart DE GOEIJ, Simone DE HAIJ, Thilo RIEDL, Rene HOET, Ole BAADSGAARD, Jan VAN DE WINKEL, David SATIJN, Paul PARREN, Aran Frank LABRIJN, Joyce MEESTERS, Janine SCHUURMAN, Edward N. VAN DEN BRINK
  • Publication number: 20180179286
    Abstract: Isolated monoclonal antibodies which bind to human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.
    Type: Application
    Filed: December 5, 2017
    Publication date: June 28, 2018
    Inventors: Bart DE GOEIJ, Simone DE HAIJ, Thilo RIEDL, Rene HOET, Ole BAADSGAARD, Jan VAN DE WINKEL, David SATIJN, Paul PARREN, Aran Frank LABRIJN, Joyce MEESTERS, Janine SCHUURMAN, Edward N. VAN DEN BRINK
  • Patent number: 10000570
    Abstract: The present invention relates to positions in the constant region of antibodies, in particular the CH3 region of IgG4, which affect the strength of CH3-CH3 interactions. Mutations that either stabilize or destabilize this interaction are disclosed.
    Type: Grant
    Filed: June 15, 2015
    Date of Patent: June 19, 2018
    Assignee: Genmab A/S
    Inventors: Aran Frank Labrijn, Stefan Loverix, Paul Parren, Jan Van De Winkel, Janine Schuurman, Ignace Lasters
  • Patent number: 9862769
    Abstract: Isolated monoclonal antibodies which bind to human epidermal growth factor receptor 2 (HER2), and related anti-body-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.
    Type: Grant
    Filed: May 27, 2011
    Date of Patent: January 9, 2018
    Assignee: GENMAB A/S
    Inventors: Bart De Goeij, Simone De Haij, Thilo Riedl, Rene Hoet, Ole Baadsgaard, Jan Van De Winkel, David Satijn, Paul Parren, Aran Frank Labrijn, Joyce Meesters, Janine Schuurman, Edward N. Van Den Brink
  • Publication number: 20170369590
    Abstract: Bispecific antibodies which comprise antigen-binding regions binding to two different epitopes of human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and methods of preparing and using the antibodies are also disclosed.
    Type: Application
    Filed: May 18, 2017
    Publication date: December 28, 2017
    Inventors: Bart DE GOEIJ, Patrick VAN BERKEL, Kristin STRUMANE, Aran Frank LABRIJN, Joost J. NEIJSSEN, Joyce I. MEESTERS, Paul PARREN, Janine SCHUURMAN
  • Publication number: 20170369594
    Abstract: Bispecific antibodies which comprise one antigen-binding region binding to an epitope of human epidermal growth factor receptor 2 (HER2) and one antigen-binding region binding to human CD3, and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and methods for preparing and using the antibodies are also disclosed.
    Type: Application
    Filed: May 18, 2017
    Publication date: December 28, 2017
    Inventors: Joost J. NEIJSSEN, Joyce I. MEESTERS, Bart DE GOEIJ, Aran Frank LABRIJN, Paul PARREN, Janine SCHUURMAN
  • Publication number: 20170320962
    Abstract: Isolated monoclonal antibodies which bind to human c-Met, the hepatocyte growth factor receptor, and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.
    Type: Application
    Filed: April 19, 2017
    Publication date: November 9, 2017
    Inventors: Joost J. NEIJSSEN, Bart DE GOEIJ, Edward Norbert VAN DEN BRINK, Aran Frank LABRIJN, Rene HOET, Janine SCHUURMAN, Paul PARREN, Jan VAN DE WINKEL
  • Publication number: 20170313782
    Abstract: Isolated monoclonal antibodies which bind to human c-Met, the hepatocyte growth factor receptor, and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.
    Type: Application
    Filed: April 11, 2017
    Publication date: November 2, 2017
    Inventors: Joost J. NEIJSSEN, Bart DE GOEIJ, Edward Norbert VAN DEN BRINK, Aran Frank LABRIJN, Rene HOET, Janine SCHUURMAN, Paul PARREN, Jan VAN DE WINKEL
  • Publication number: 20170233497
    Abstract: Novel heterodimeric antibody-Fc-containing proteins, such as bispecific antibodies, and novel methods for producing such proteins
    Type: Application
    Filed: January 24, 2017
    Publication date: August 17, 2017
    Inventors: Aran Frank LABRIJN, Joyce I. MEESTERS, Ewald T. J. VAN DEN BREMER, Joost J. NEIJSSEN, Patrick VAN BERKEL, Bart DE GOEIJ, Tom VINK, Jan VAN DE WINKEL, Janine SCHUURMAN, Paul PARREN
  • Patent number: 9663578
    Abstract: Isolated monoclonal antibodies which bind to human CD32b and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, and therapeutic and diagnostic methods for using the antibodies.
    Type: Grant
    Filed: June 27, 2014
    Date of Patent: May 30, 2017
    Assignee: GENMAB A/S
    Inventors: Edward Norbert Van Den Brink, Paul Parren, Jan Van De Winkel, Aran Frank Labrijn, Frank Everhardus Martinus Rebers, Esther Cornelia Wilhelmina Breij
  • Patent number: 9657107
    Abstract: Isolated monoclonal antibodies which bind to human c-Met, the hepatocyte growth factor receptor, and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.
    Type: Grant
    Filed: May 26, 2015
    Date of Patent: May 23, 2017
    Assignee: GENMAB A/S
    Inventors: Joost J. Neijssen, Bart De Goeij, Edward Norbert Van Den Brink, Aran Frank Labrijn, Rene Hoet, Janine Schuurman, Paul Parren, Jan Van De Winkel
  • Publication number: 20170037138
    Abstract: The invention relates to novel non-human transgenic animals, which upon antigenic stimulation are capable of producing monovalent antibodies binding to a selected antigen, modified heavy chain transgenes, methods for producing the non-human transgenic animals, methods for immunizing the non-human transgenic animals for as well as monovalent antibodies obtainable by such immunization methods.
    Type: Application
    Filed: March 17, 2016
    Publication date: February 9, 2017
    Inventors: Janine SCHUURMAN, Tom VINK, Jan VAN DE WINKEL, Aran Frank LABRIJN, Paul PARREN, Willem Karel BLEEKER, Frank BEURSKENS, Patrick VAN BERKEL
  • Publication number: 20160333095
    Abstract: The present invention relates to humanized or chimeric antibodies binding CD3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment.
    Type: Application
    Filed: January 8, 2015
    Publication date: November 17, 2016
    Applicant: GENMAB A/S
    Inventors: Edward Norbert VAN DEN BRINK, Joost J. NEIJSSEN, Aran Frank LABRIJN, Joyce MEESTERS, Janine SCHUURMAN, Isil ALTINTAS, Paul PARREN, Rik RADEMAKER
  • Publication number: 20160168247
    Abstract: The present invention relates to humanized or chimeric antibodies binding CD3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment.
    Type: Application
    Filed: July 4, 2014
    Publication date: June 16, 2016
    Inventors: Edward VAN DEN BRINK, Joost J. NEIJSSEN, Aran Frank LABRIJN, Joyce MEESTERS, Janine SCHUURMAN, Paul PARREN